Molecular methods for neuropathic pain treatment

Journal of Neuropathic Pain and Symptom Palliation

Volumn 1, Issue 3, 2006, Pages 35-43

  Siniscalco, Dario ^a   Fuccio, Carlo ^a   De Novellis, Vito ^a   Rossi, Francesco ^a   Maione, Sabatino ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Gene therapy; Neuropathic pain; Nociceptive neurotransmitters; Stem cell; Virus therapy

Indexed keywords

EID: 33746916749     PISSN: 15437698     EISSN: 15437701     Source Type: Journal    
DOI: 10.1300/J426v01n03_04     Document Type: Article

References (76)

1. Merskey H.; Bogduk N. Classification of chronic pain, IASP press: Seattle, 1994.
2. de Novellis V.; Siniscalco D.; Galderisi U.; Fuccio C.; Nolano M.; Santoro L.; Cascino A.; Roth K.A.; Rossi F.; Maione S. Blockade of glutamate mGlu5 receptors in a rat model of neuropathic pain prevents early over-expression of pro-apoptotic genes and morphological changes in dorsal horn lamina II. Neuropharmacology, 2004; 46, 468-479.
3. Bonica JJ. In Advances in Pain Research and Therapy, Raven Press: New York, 1970; pp. 141-166.
4. Kandel E.R.; Schwartz J.H.; Jessel T.M. In Principles of Neural Science, McGraw-Hill: New York, 4th ed., 2000.
5. Woolf C.J.; Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 1999; 353: 1959-1964.
6. Coderre T.J.; Katz J.; Vaccarino A.L.; Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain, 1993; 52: 259-285.
7. Mendell L.M. Physiological properties of unmyelinated fiber projection to the spinal cord. Exp Neurol, 1996; 16: 316-332.
8. Doubell T.P.; Mannion R.J.; Woolf C.J. In Textbook of Pain, 4th ed. Churchill Livingstone: London, 1999; 165-182.
9. Hua X.Y.; Chen P.; Yaksh T.L. Inhibition of spinal protein kinase C reduces nerve injury-induced tactile allodynia in neuropathic rats. Neurosci Lett, 1999; 276: 99-102.
10. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol, 2001; 429: 23-37.
11. Maione S.; Siniscalco D.; Galderisi U.; de Novellis V.; Uliano R.; Di Bernardo G.; BerrinoL.; Cascino A.; Rossi F. Apoptotic genes expression in the lumbar dorsal horn in a model of neuropathic pain in rat. Neuroreport, 2002; 13: 101-106.
12. Wall P.D.; Gutnick M. Ongoing activity in peripheral nerves: the physiology and pharmacology of impulses originating from a neuroma. Exp Neurol 1974; 43: 580-93.
13. Gold M.S. Spinal nerve ligation: what to blame for the pain and why. Pain, 2000; 84, 117-120.
14. Waxman S.G.; Kocsis J.D.; Black J.A. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol, 1994; 72: 466-470.
15. Cervero F.; Laird J.M.A. Role of ion channels in mechanisms controlling gastrointestinal pain pathways. Curr Opin Pharmacol, 2003; 3: 608-612.
16. Black J.A.; Langworthy K.; Hinson A.W.; Dib Hajj S.D.; Waxman S.G. NGF has opposing effects on Na+ channel III and SNS gene expression in spinal sensory neurons. Neuroreport, 1997; 8: 2331-2335.
17. Xiao W.H.; Bennett G.J. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther, 1995; 274: 666-672.
18. Amir R.; Devor M. Chemically mediated cross-excitation in rat dorsal root ganglia. J Neurosci, 1996; 16: 4733-4741.
19. Ro L.; Chen S.; Tang L.; Chang H. Local application of anti-NGF blocks the collateral sprouting in rats following chronic constriction injury of the sciatic nerve. Neurosci Lett, 1996; 218: 87-90.
20. Sorkin L.S.; Doom C.M. Epineural application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J Peripher Syst, 2000; 5: 96-100.
21. Ignatowski T.A.; Covey W.C.; Knight P.R.; Severin C.M.; Nickola T.J.; Spengler R.N. Brain-derived TNFalpha mediates neuropathic pain. Brain Res, 1999; 841: 70-77.
22. Bach F.W.; Jensen T.S.; Kastrup J.; Stigsby B.; Dejgard A. The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain, 1990; 40: 29-34.
23. Cattabeni F. Ralfinamide. Newron Pharmaceuticals. IDrugs, 2004; 7: 935-939.
24. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther, 1997; 74: 129-180.
25. Davar G.; Hama A.; Deykin A.; Vos B.; Maciewicz R. MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy. Brain Res, 1991; 553: 327-330.
26. Mao J.; Price D.D.; Mayer D.J.; Lu J.; Hayes R.L. Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy. Brain Res, 1992; 576: 254-262.
27. Sotgiu M.L.; Biella G. Differential effects of MK-801, a N-methyl-D-aspartate non-competitive antagonist, on the dorsal horn neuron hyperactivity and hyperexcitability in neuropathic rats. Neurosci Lett, 2000; 283: 153-156.
28. Rabben T.; Skjelbred P.; Oye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther, 1999; 289: 1060-1066.
29. Jasik M. Therapy of diabetic neuropathy. Przegl Lek, 2003; 60: 167-169.
30. Hewitt D.J. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain, 2000; 16: 73-79.
31. Quartaroli M.; Carignani C.; Dal Forno G. et al. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A. J Pharmacol Exp Ther, 1999; 290: 158-169.
32. Christensen D.; Gautron M.; Guilbaud G.; Kayser V. Combined systemic administration of the glycine/NMDA receptor antagonist, (+)-HA966 and morphine attenuates pain-related behaviour in a rat model of trigeminal neuropathic pain. Pain, 1999; 83: 433-440.
33. Zhu C.Z., Hsieh G., Ei-Kouhen O., Wilson S.G., Mikusa J.P., Hollingsworth P.R., Chang R., Moreland R.B., Brioni J., Decker M.W., Honore P. Role of central and peripheral mGluR5 receptors in post-operative pain in rats. Pain, 2005; 114(1-2): 195-202.
34. Likar R., Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg, 2005; 100: 781-785.
35. Maneuf Y.P.; Gonzalez M.I.; Sutton K.S.; Chung F.Z.; Pinnock R.D.; Lee K. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci, 2003; 60: 742-750.
36. Johnson S.; Johnson F.N.; Johnson R.D.; Armer M.L. In Reviews in Contemporary Pharmacotherapy, Marius Press: Carnforth; 2001; 125-211.
37. Urban M.O., Ren K., Park K.T., Campbell B., Anker N., Stearns B., Aiyar J., Belley M., Cohen C., Bristow L. Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. J Pharmacol Exp Ther, 2005; 313: 1209-1216.
38. Dahl J.B.; Mathiesen O.; Moiniche S. 'Protective premedication': an option with gabapentin and related drugs? A review of gabapentin and pregabalin in in the treatment of post-operative pain. Acta Anaesthesiol Scand, 2004; 48: 1130-1136.
39. Wang S.; Lim G.; Zeng Q.; Sung B.; Ai Y.; Guo G.; Yang L.; Mao J. Expression of central glucocorticoid receptors after peripheral nerve injury contributes to neuropathic pain behaviors in rats. J Neurosci, 2004; 24: 8595-8605.
40. Szolcsanyi J.; Bolcskei K.; Szabo A.; Pinter E.; Petho G.; Elekes K.; Borzsei R.; Almasi R.; Szuts T.; Keri G.; Helyes Z. Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. Eur J Pharmacol, 2004; 498: 103-109.
41. Obata K.; Noguchi K. MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci, 2004; 74: 2643-2653.
42. Jin S.X.; Zhuang Z.Y.; Woolf C.J.; Ji R.R. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci, 2003; 23: 4017-4022.
43. Ciruela A.; Dixon A.K.; Bramwell S.; Gonzalez M.I.; Pinnock R.D.; Lee K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol, 2003; 138: 751-756.
44. Obata H., Conklin D., Eisenach J.C. Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain, 2005; 113: 271-276.
45. Dib Hajj S.D.; Fjell J.; Cummins T.R. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain, 1999; 83: 591-600.
46. Devor M.; Keller C.H.; Deerinck T.J.; Levinson S.R.; Ellisman M.H. Na+ channel accumulation on axolemma of afferent endings in nerve end neuromas in Apteronotus. Neurosci Lett, 1989; 102: 149-154.
47. Hains B.C.; Saab C.Y.; Klein J.P.; Craner M.J.; Waxman S.G. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J Neurosci, 2004; 24: 4832-4839.
48. Lai J.; Gold M.S.; Kim C.S.; Bian D.; Ossipov M.H.; Hunter J.C.; Porreca F. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain, 2002; 95: 143-152.
49. Valder C.R.; Liu J.J.; Song Y.H.; Luo Z.D. Coupling gene chip analyses and rat genetic variances in identifying potential target genes that may contribute to neuropathic allodynia development. J Neurochem, 2003; 87: 560-573.
50. Li C.Y.; Song Y.H.; Higuera E.S.; Luo Z.D. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci, 2004; 24: 8494-8499.
51. Vincler M.A., Eisenach J.C. Knock down of the alpha 5 nicotinic acetylcholine receptor in spinal nerve-ligated rats alleviates mechanical allodynia. Pharmacol Biochem Behav, 2005; 80: 135-143.
52. Garry M.G.; Malik S.; Yu J.; Davis M.A.; Yang J. Knock down of spinal NMDA receptors reduces NMDA and formalin evoked behaviors in rat. Neuroreport, 2000; 11: 49-55.
53. Przewlocka B.; Sieja A.; Starowicz K.; Maj M.; Bilecki W.; Przewlocki R. Knockdown of spinal opioid receptors by antisense targeting beta-arrestin reduces morphine tolerance and allodynia in rat.Neurosci Lett, 2002; 325: 107-110.
54. Kennedy C.; Assis T.S.; Currie A.J.; Rowan E.G. Crossing the pain barrier: P2 receptors as targets for novel analgesics. J Physiol, 2003; 553: 683-694.
55. Honore P.; Kage K.; Mikusa J.; Watt A.T.; Johnston J.F.; Wyatt J.R.; Faltynek C.R.; Jarvis M.F.; Lynch K. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain, 2002; 99: 11-19.
56. Huang W.; Simpson R.K. Jr. Antisense of c-fos gene attenuates Fos expression in the spinal cord induced by unilateral constriction of the sciatic nerve in the rat. Neurosci Lett, 1999; 263: 61-64.
57. Palazzo E., Genovese R., Mariani L., Siniscalco D., Marabese I., de Novellis V., Rossi F., Maione S. Metabotropic glutamate receptor 5 and dorsal raphe serotonin release in inflammatory pain in rat. Eur J Pharmacol 2004; 492: 169-176.
58. Hernandez A., Constandil L., Laurido C., Pelissier T., Marchand F., Ardid D., Alloui A., Eschalier A., Soto-Moyano R. Venlafaxine-induced depression of wind-up activity in mononeuropathic rats is potentiated by inhibition of brain 5-HT1A receptor expression in vivo. Int J Neurosci, 2004; 114: 229-242.
59. Hains B.C., Johnson K.M., Eaton M.J., Willis W.D., Hulsebosch C.E. Serotonergic neural precursor cell grafts attenuate bilateral hyperexcitability of dorsal horn neurons after spinal hemisection in rat. Neuroscience, 2003; 116: 1097-1110.
60. Schultz S.S. Adult stem cell application in spinal cord injury. Curr Drug Targets, 2005; 6: 63-73.
61. Klein S., Svendsen C.N. Stem cells in the injured spinal cord: reducing the pain and increasing the gain. Nature Neurosci, 2005; 8: 259-260.
62. Lin C.R.; Wu P.C.; Shih H.C.; Cheng J.T.; Lu C.Y.; Chou A.K.; Yang L.C. Intrathecal spinal progenitor cell transplantation for the treatment of neuropathic pain. Cell Transplant, 2002 ; 11 : 17-24.
63. Moore K.A.; Kohno T.; Karchewski L.A.; Scholz J.; Baba H.; Woolf C.J. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci, 2002; 22: 6724-6731.
64. Liu J.; Wolfe D.; Hao S.; Huang S.; Glorioso J.C.; Mata M.; Fink D.J. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther, 2004; 10: 57-66.
65. Wilson S.P.; Yeomans D.C. Virally mediated delivery of enkephalin and other neuropeptide transgenes in experimental pain models. Ann NY Acad Sci, 2002; 971: 515-521.
66. Pradat P.F.; Kennel P.; Naimi-Sadaoui S.; Finiels F.; Orsini C.; Revah F.; Delaere P.; Mallet J. Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer. Hum Gene Ther, 2001; 12: 2237-2249.
67. Eaton M.J.; Blits B.; Ruitenberg M.J.; Verhaagen J.; Oudega M. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther, 2002; 9: 1387-1395.
68. Tang X.Q.; Tanelian D.L.; Smith G.M. Semaphorin3A inhibits nerve growth factor-induced sprouting of nociceptive afferents in adult rat spinal cord. J Neurosci, 2004; 24: 819-827.
69. Dong Z.Q., Ma F., Xie H., Wang Y.Q., Wu G.C. Changes of expression of glial cell line-derived neurotrophic factor and its receptor in dorsal root ganglions and spinal dorsal horn during electroacupuncture treatment in neuropathic pain rats. Neurosci Lett, 2005; 376: 143-148.
70. Wu C.M.; Lin M.W.; Cheng J.T.; Wang Y.M.; Huang Y.W.; Sun W.Z.; Lin C.R. Regulated, electroporation-mediated delivery of pro-opiomelanocortin gene suppresses chronic constriction injury-induced neuropathic pain in rats. Gene Ther, 2004 11: 933-940.
71. Juurlink B.H., Paterson P.G. Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. J Spinal Cord Med, 1998; 21: 309-334.
72. Kamencic H., Griebel R.W., Lyon A.W., Paterson P.G., Juurlink B.H. Promoting glutathione synthesis after spinal cord trauma decreases secondary damage and promotes retention of function. FASEB J, 2001; 15: 243-250.
73. Joseph E.K., Levine J.D. Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci, 2004; 20: 2896-2902.
74. Yao M.Z.; Gu J.F.; Wang J.H.; Sun L.Y.; Liu H.; Liu X.Y. Adenovirus-mediated interleukin-2 gene therapy of nociception. Gene Ther, 2003; 10: 1392-1399.
75. Eaton M.J.; Karmally S.; Martinez M.A.; Plunkett J.A.; Lopez T.; Cejas P.J. Lumbar transplant of neurons genetically modified to secrete galanin reverse pain-like behaviors after partial sciatic nerve injury. Peripher Nerv Syst, 1999; 4:245-257.
76. Fine P.G., Miaskowski C., Paice J.A. Meeting the challenges in cancer pain management. J Support Oncol, 2004; 2: 5-22.